Dr. Yang Zhang 张扬
Chief Physician
Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of lung cancer, esophageal cancer, and mediastinal tumors. Specializes in single-port thoracoscopic minimally invasive surgery.
Dr. Zhang holds an MD and serves as Chief Physician and Master’s supervisor at Fudan University Shanghai Cancer Center. The doctor leads three National Natural Science Foundation projects. Twelve papers contributed to seven international lung cancer guidelines. Dr. Zhang was third contributor to a project winning the 2023 Chinese Medical Association Science and Technology Award First Prize.
Professional roles
- Member, Multidisciplinary Clinical Science Committee, International Association for the Study of Lung Cancer (IASLC)
Name order: in Chinese the family name comes first (Zhang Yang). Papers usually list the name as Yang Zhang or Zhang Y.
Selected publications
199 papers on PubMed matched by name and affiliation; 46 as first or senior author since 2016. Most recent first- or senior-author papers:
- Crit Rev Oncol Hematol, 2026 (senior author): Mitophagy in lymph node metastasis: Mechanisms, immune consequences and therapeutic opportunities. PubMed 42191100
- Ann Surg, 2026 (first author): Feasibility of Wedge Resection for Subpleural Hilar Lung Nodules Using CT-guided Hookwire Localization and Ultrasonic Dissection. PubMed 42083084
- Cancer Biol Med, 2026 (first author): Single-cell and spatial transcriptome analyses reveal tumor immunometabolism in lymph node metastasis of lung cancer. PubMed 41711463
- JTCVS Tech, 2026 (senior author): Uniportal thoracoscopic mediastinal lymph node dissection: Technical pearls and anatomical considerations. PubMed 41658883
- J Clin Oncol, 2025 (first author): Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity-Dominant Lung Adenocarcinoma. PubMed 40690727
- Lung Cancer, 2025 (senior author): A Reply to comment on "Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small cell lung cancer: A phase II, prospective cohort study". PubMed 40473340
- J Thorac Dis, 2024 (first author): Protocol of a single-arm, multicenter, phase III trial for selective lymph node dissection in cT1N0M0 invasive non-small cell lung cancer with consolidation-tumor ratio >0.5 located in the apical segment: Eastern Cooperative Thoracic Oncology Projects ECTOP-1018 (SELLAS study). PubMed 39678839
- Thorac Cancer, 2024 (first author): Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real-world analysis. PubMed 38532546
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion